P2RY6

P2Y purinoceptor 6 · Q15077 · P2RY6 on Sugi Atlas →

58,901 patent compounds predicted against P2RY6, 33,341 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL148675	0.73	14/20
SCHEMBL148676	0.73	14/20
SCHEMBL39904	0.72	14/20
SCHEMBL154172	0.72	14/20
SCHEMBL308618	0.72	14/20
SCHEMBL532547	0.72	14/20
SCHEMBL475344	0.51	14/20
SCHEMBL498723	0.66	13/20
SCHEMBL498724	0.66	13/20
SCHEMBL112172	0.55	13/20
SCHEMBL150274	0.59	12/20
SCHEMBL95680	0.54	12/20
SCHEMBL121732	0.67	11/20
Choline (SCHEMBL503811)	0.65	11/20
Uridine (SCHEMBL338288)	0.62	11/20
Cytarabine 5'-Phosphate (SCHEMBL27306)	0.59	11/20
SCHEMBL432100	0.81	10/20
Cystetine Triphosphate (SCHEMBL104629)	0.71	10/20
Cystetine Triphosphate (SCHEMBL104630)	0.71	10/20
Cystetine Triphosphate (SCHEMBL105273)	0.71	10/20

Clinical trials — most relevant to P2RY6 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
H2 Haplotype and CYP3As Polymorphisms and the Antiplatelet Response to Clopidogrel	PHASE4	COMPLETED
Effect of Methylnaltrexone on the PK/PD Profiles of Ticagrelor in Patients Treated With Morphine	PHASE4	COMPLETED
Reversal of the Anti-platelet Effects of Ticagrelor	PHASE4	COMPLETED
Genotype-Guided Abbreviated DAPT Versus Un-Guided De-escalation Therapy in Patients With ACS and HBR	PHASE4	NOT_YET_RECRUITING
PD and PK Profiles of Switching Between Cangrelor and Ticagrelor Following Ticagrelor Pre-treatment	PHASE4	COMPLETED
Add-on Cangrelor in STEMI-triggered Cardiac Arrest	PHASE4	UNKNOWN
Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function: a Validation Study	PHASE4	COMPLETED
Pharmacodynamic and Pharmacokinetic of Switching From Cangrelor to Prasugrel in ACS Patients Undergoing PCI	PHASE4	COMPLETED
Pharmacodynamic Comparison of Omeprazole Versus Pantoprazole on Platelet Reactivity in Patients With Acute Coronary Syndromes on Dual Antiplatelet Therapy With New P2Y12 Inhibitors -Trial dOPPLER-	PHASE4	UNKNOWN
The Effect of IV Cangrelor and Oral Ticagrelor Study	PHASE4	COMPLETED
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial	PHASE4	COMPLETED
Ticagrelor And PrEconditioning in Patients With coronaRy Artery diSease	PHASE2/PHASE3	COMPLETED
Clopidogrel and Response Variability Investigation Study 2	PHASE3	COMPLETED
Study in Diabetes Mellitus Patients Without Prior Myocardial Infarction or Stroke Undergoing Elective Percutaneous Coronary Intervention.	PHASE3	WITHDRAWN
Platelet Inhibition With Ticagrelor 60 mg Versus Ticagrelor 90 mg in Elderly Patients With ACS	PHASE3	COMPLETED
Study of the Long-term Effects of P2Y12 Inhibitor Monotherapy and Coagulation Markers After Percutaneous Coronary Angioplasty.	PHASE3	RECRUITING
Trimetazidine as an Adjunct to Enhance Clopidogrel Response.	PHASE2	COMPLETED
POPular GUILTY PILOT: Genotype-guided Clopidogrel Monotherapy	PHASE2	RECRUITING
The Impact of Genotype on Pharmacokinetics and Antiplatelet Effects of Ticagrelor in Healthy Chinese	PHASE1	COMPLETED
Influence of CYP2C19 Genetic Variants on Clopidogrel in Healthy Subjects	PHASE1	COMPLETED
Pyridoxine, P2 Receptor Antagonism, and ATP-mediated Vasodilation in Young Adults	EARLY_PHASE1	COMPLETED
Salts of Clopidogrel: Investigation to ENsure Clinical Equivalence	nan	COMPLETED
Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders	nan	UNKNOWN
Genotyping GUided Antiplatelet theRapy in pAtieNts Treated With Drug Eluting stEnts (GUARANTEE)	nan	ACTIVE_NOT_RECRUITING
Assessment of Prospective CYP2C19 Genotype Guided Dosing of Anti-Platelet Therapy in Percutaneous Coronary Intervention	nan	COMPLETED
Pharmacodynamic Effect of Prasugrel vs. Ticagrelor in Diabetes	nan	COMPLETED
Downstream Molecular Signals of P2Y12 Receptors in Hyporeactive Patients Under Clopidogrel Treatment A Possible Mechanism of HOTPR(High On-Treatment Platelet Reactivity)	nan	COMPLETED
Suppressive Functions of Regulatory T Cells in Migraine	nan	NOT_YET_RECRUITING
Comparison Between P2Y12 Antagonist Monotherapy and Dual Antiplatelet Therapy After DES	nan	UNKNOWN
Impact of Ticagrelor Re-load on Pharmacodynamic Profiles	nan	COMPLETED

Related proteins — ESM-2 sequence neighbours (a P2RY6 binder may also engage these)

Protein	Name	Similarity
Q63371	—	1.000	Q63371 →
Q9ERK9	—	1.000	Q9ERK9 →
Q5YA25	—	0.983	Q5YA25 →
O35811	—	0.981	O35811 →
P2RY4	P2Y purinoceptor 4	0.981	landscape →
P35383	—	0.978	P35383 →
P41232	—	0.977	P41232 →
Q9JJS7	—	0.974	Q9JJS7 →
P2RY2	P2Y purinoceptor 2	0.974	landscape →
Q86VZ1	—	0.966	Q86VZ1 →
O93361	—	0.963	O93361 →
Q98907	—	0.963	Q98907 →
Q99PE4	—	0.958	Q99PE4 →
Q56UD9	—	0.954	Q56UD9 →
Q5KSK8	—	0.954	Q5KSK8 →
NPBWR1	Neuropeptides B/W receptor type 1	0.954	landscape →
FFAR2	Free fatty acid receptor 2	0.952	landscape →
LTB4R	Leukotriene B4 receptor 1	0.952	landscape →
Q8BUD0	—	0.952	Q8BUD0 →
P49681	—	0.950	P49681 →
Q8VCK6	—	0.950	Q8VCK6 →
Q76EI6	—	0.950	Q76EI6 →
O88855	—	0.950	O88855 →
GPR35	G-protein coupled receptor 35	0.950	landscape →
P58825	—	0.950	P58825 →
Q3T181	—	0.950	Q3T181 →
Q8MJV3	—	0.949	Q8MJV3 →
GPR4	G-prodeshotein coupled receptor 4	0.949	landscape →
Q9R0Q2	—	0.949	Q9R0Q2 →
Q1JQB3	—	0.948	Q1JQB3 →